

Curriculum vitae Prof. dr. Leo A.B. Joosten

Personal Information:

Family name, First name: Joosten, Leo A.B (Leonardus Antonius Bernardus)

Researcher unique identifier(s): ORCID: 0000-0001-6166-9830, Research ID: H-3138-2015

Date of birth: September 11, 1958

Nationality: Dutch

URL for web site: www.radboudumc.nl > en > [peopleProf. dr. Leo Joosten - Radboudumc](http://peopleProf.dr.LeoJoosten-Radboudumc)

Education

10/12/1999 PhD, Radboud University Medical Centre, Department of Rheumatology, Nijmegen, The Netherlands.

01/07/1982 Bachelor, HAN University of Applied Sciences, Nijmegen, The Netherlands.

Current positions

2014-Present, Professor of Mechanisms of Inflammatory Diseases, Radboud University Medical Centre, Department of Internal Medicine, Nijmegen, The Netherlands.

2019-Present, Visiting Professor, Department of Medicine, Clinical Immunology & Rheumatology, UAB, Birmingham, Alabama, USA

2020-Present, Visiting Professor, Faculdade da Polícia Militar do Estado de Goiás, Goiânia, Goiás, Brasil.

2022-Present, Distinguished Visiting Professor, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

2023-Present, Professor and Project leader HINT-II (PNRR-III-C9-2022-I8, CF85/15.11.2022), University of Medicine and Pharmacy „Iuliu Hațieganu”, Department of Medical Genetics, Cluj-Napoca, Romania

2024, Visiting professor, Department of Rheumatology, Lariboisier Hospital, Université Paris Cité, Paris, France

Previous positions

2023, Visiting professor, Department of Rheumatology, Lariboisier Hospital, Université Paris Cité, Paris, France

2016-2019, Professor and Project leader HINT, EU-POC P_37_762, University of Medicine and Pharmacy „Iuliu Hațieganu”, Department of Medical Genetics, Cluj-Napoca, Romania

2012-2019, Research fellow (3 months / year), Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado, USA.

2007-2014, Associate Professor of Experimental Medicine (UHD) Head of the laboratory of Experimental Medicine, Radboudumc, Nijmegen, The Netherlands

1996-2007, PhD-student, Postdoc & Assistant Professor, Department of Rheumatology, Radboudumc, Nijmegen, The Netherlands

Supervision of graduate students and postdoctoral fellows

2014-Present, Postdocs 14; PhD students 58; Master Students 38. Radboud University Medical Centre, Departments of Rheumatology and Internal Medicine, Nijmegen, The Netherlands

2016-Present, Postdocs 2, PhD students 7, Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Major collaborations

Prof. C.A. Dinarello, Studies on the role of IL-1/IL-18/IL-32 in inflammation, University of Colorado, Denver, USA. **Prof. T. Kanneganti**, Studies on the role of the “Inflammasome” in inflammation, St Jude’s Hospital, Memphis, USA. **Prof. L.A. O’Neill**, Studies on IL-1 in inflammation and Innate Immunity, Trinity College, Dublin, Ireland. **Prof. E. Latz**, Studies in Innate Immunity and Trained Immunity, University of Bonn, Bonn, Germany. **Prof. J. Schultze**, Studies on

transcriptomics and genomics, DZNE, Helmholtz Institute, Bonn, Germany. **Prof. Y. Li**, Studies on Single Cell transcriptomics in Inflammation, Helmholtz Institute for Infections, Hannover, Germany. **Prof. T.R. Merriman**, Studies on Genetics in Gout, University of Birmingham, Alabama, USA. **Prof. M. Mhlanga**, Studies on LncRNA's in inflammation, Radboud University, Nijmegen, The Netherlands. **Prof. M.G. Netea**, Studies on Trained Immunity, Radboud University Medical Center, Nijmegen, The Netherlands. **Professors K. Ea, F. Liote and P. Richette**, studies in gout and osteoarthritis, University of Paris, Paris, France. **Prof. J.A. Chabalgoity**, studies in immunotherapy in cancer, University of Montevideo, Montevideo, Uruguay. **Prof. S. Rednic**, studies on hyperuricemia and gout, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

References

1. Ter Horst R, ..., **Joosten LAB***, Netea MG. * Host and Environmental Factors Influencing Individual Human Cytokine Responses. *Cell* 167:1111-1124. 2016. Article. Category Q1. Rank 3. doi: 10.1016/j.cell.2016.10.018. **IF 68,86** *Shared senior authorship.
2. Oosting M, ..., Netea MG, **Joosten LA**. Functional and Genomic Architecture of *Borrelia burgdorferi*-Induced Cytokine Responses in Humans. *Cell Host Microbe*. 20(6):822-833. 2016. Article. Category Q1. Rank 4. doi: 10.1016/j.chom.2016.10.006. **IF 27.29**
3. Crișan TO, ..., **Joosten LA**. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. *Ann Rheum Dis*. 75(4):755-62. 2016. Article. Category Q1. Rank 3. doi: 10.1136/annrheumdis-2014-206564. **IF 28.00**
4. Crișan TO, ..., Joosten LAB. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. *Proc Natl Acad Sci U S A*. 114(21):5485-5490. 2017. Article. Category Q1. Rank 9. doi: 10.1073/pnas.1620910114. **IF 12.78**
5. **Joosten LAB**, Crișan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. *Nat Rev Rheumatol*. 16(2):75-86. 2020. Review. Category Q1. Rank 2. doi: 10.1038/s41584-019-0334-3. **IF 32.29**
6. Klück V, ..., Dinarello CA, Joosten LA. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. *Ann Rheum Dis*. 79(4):536-544. 2020. Article. Category Q1. Rank 3. doi: 10.1136/annrheumdis-2019-216233. **IF 28.00**
7. Cabău G, ..., **Joosten LAB**. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. *Immunol Rev*. 294(1):92-105. 2020. Review. Category Q1, Rank 23. doi: 10.1111/imr.12833. **IF 10.98**
8. Klück V, ..., Dinarello CA, **Joosten LAB**. Dapansutril, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. *Lancet Rheumatol*. 2(5):e270-e280. 2020. Article. Category Q1. Rank 1. doi: 10.1016/s2665-9913(20)30065-5. **IF 35.48**
9. Van Puffelen JH, ..., **Joosten LAB***, Vermeulen SH*. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. *Nat Rev Urol*. 17(9):513-525. 2020. Review. Category Q1. Rank 4. doi: 10.1038/s41585-020-0346-4. **IF 14.43** *Shared senior authorship.
10. Netea MG, **Joosten LAB**. Beyond adaptive immunity: induction of trained immunity by COVID-19 adenoviral vaccines. *J Clin Invest*. 2023 Jan 17;133(2):e166467. doi: 10.1172/JCI166467.

Nov 19th, 2024.

Prof. dr. L.A.B. Joosten